A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 36
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : AA
Long Form : antiandrogen
No. Year Title Co-occurring Abbreviation
2020 Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals. AR, MRONJ
2019 Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. CAB, cT2, FACT-P, HT, LHRHa, PCa, PSA, pT3, QOL, RP
2019 Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. DMAb, mRCC, ONJ, RCC, SREs
2019 Efficacy and safety of combined androgen blockade with antiandrogen for advanced prostate cancer. cab, CIs, hrs, nsaa, OS, PCa, PFS, RCTs, saa
2019 How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer. CRPC
2018 anti-PD-1, ICP, TKI, TME
2018 Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. ADT, CIs, DVT, GnRH, HRs, PCa, PE, TEs
2018 Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. COC, GRADE, HOMA-IR, MD, OR, PCOS, SMD
2018 Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events-a meta-analysis. ATE, DB, ORs, VTE
10  2017 Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death. ADT, aHR, CI, PC
11  2017 Effects of Steroidal Antiandrogen or 5-alpha-reductase Inhibitor on Prostate Tissue Hormone Content. 5ARI, BPH, CMA, DHT, DUTA
12  2017 Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Groupstudy. CI, mChRCC, mTOR, OS, RCC, TT, TTF, VEGF
13  2017 Removal of novel antiandrogens identified in biological effluents of domestic wastewater by activated carbon. AAs, EDA, GAC, HPLC, YAS
14  2017 Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality. NSCLC, RCC, VEGF, VEGFR
15  2017 Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. CCs, HIFs
16  2017 The "inherent vice" in the anti-angiogenic theory may cause the highly metastatic cancer to spread more aggressively. ---
17  2016 Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. ADT, GnRH, PCa, PCBaSe
18  2016 Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials. CI, HRs, LHRH, ORs, PSA-PFS
19  2016 Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. ADT, CI, GnRH, PCa
20  2015 Anti-angiogenic drug delivery from hydrophilic resorbable embolization microspheres: an in vitro study with sunitinib and bevacizumab. HCC, MA, REM
21  2015 Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy. AUC, BMI, LM, OS, PFS, SFA, VFA
22  2015 Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer. CAB, CSS, J-CaP, J-CAPRA, LHRH, OS, PADT
23  2015 Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. ADT, CVD, GnRH, HR, PCa
24  2015 Widespread contamination of coastal sediments in the Transmanche Channel with anti-androgenic compounds. PAHs
25  2014 Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. ADT, CVD, CVM, GnRH, PCa
26  2014 Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. GEMOX, HCC, OS, PFS
27  2014 Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma. EBC, mRCC
28  2014 The course of metastatic prostate cancer under treatment. ---
29  2013 Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy. ADC, CT, MRI, RT, SU, SURT
30  2012 Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. ---
31  2011 Bioassay-directed identification of novel antiandrogenic compounds in bile of fish exposed to wastewater effluents. anti-YAS, WwTWs
32  2009 Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes. HRQoL, PCa, RT
33  2007 Quality of life and psychological well being in polycystic ovary syndrome. PCOS, PCOSQ, QOL
34  2006 [Local recurrence of prostate cancer: hormone therapy]. DT
35  2004 Pattern of proliferative index (Ki-67) after anti-androgen manipulation reflects the ability of irradiation to control prostate cancer. EBRT, PSA
36  2000 Nonsteroidal progestins and antiprogestins related to flutamide. AP, Pn